Reactions 1680, p214 - 2 Dec 2017 Mood switching: case report A man in his late 30s, developed mood switching following use of maprotiline [route not stated; age at the time of reaction onset not stated]. The man was diagnosed with depression in 1997 at the age of 29 and started receiving treatment. In 2007, he was diagnosed with bipolar disorder I. He again developed depression. He was then treated with milnacipran and mianserin. This treatment was not effective. Therefore, he started receiving maprotiline 20mg daily. Four days after his treatment with maprotiline, he experienced manic symptoms like irritability, money squandering, talkativeness, sleeplessness and an intense excitement feeling. The evaluation showed clinical global impression-BP score of 136. The man was discharged in October 2008, with a prescription of clonazepam, valproate, and lithium; however his depression returned subsequently. In January 2009, he started receiving treatment with lamotrigine. A month after starting this treatment, his depression was well controlled. No manic states or depressive moods recurred. Author comment: "Case 1 exhibited a high risk of mood switching induced by antidepressants." Muneoka K, et al. Add-on lamotrigine treatment for subsyndromal depression after manic or mixed states in bipolar disorder improved the quality of life. Case Reports in Medicine 2012: 736521, 2012. Available from: URL: http:// doi.org/10.1155/2012/736521 - Japan 803286013 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud